Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP2C9 | P11712 | 2/20 | 0.51 |
| ▸ | TSHR | P16473 | 2/20 | 0.51 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.51 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.51 |
| ▸ | TRPV1 | Q8NER1 | 1/20 | 0.50 |
| ▸ | GRM5 | P41594 | 1/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.48 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.48 |
| ▸ | GAA | P10253 | 1/20 | 0.48 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.48 |
| ▸ | AKR1C3 | P42330 | 1/20 | 0.48 |
| ▸ | ITGB3 | P05106 | 6/20 | 0.47 |
| ▸ | ITGA2B | P08514 | 6/20 | 0.47 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22542017 | 0.83 | HTT (0.57) | CYP2C9ALDH1A1GAASMN1; SMN2AKR1C3 | |
| SCHEMBL6600563 | 0.80 | MAPT (0.62) | CYP2C9TSHRCYP2D6CYP3A4ITGB3 | |
| SCHEMBL8838124 | 0.80 | TRPV1 (0.61) | CYP2C9TSHRCYP2D6CYP3A4TRPV1 | |
| SCHEMBL20884943 | 0.79 | SMN1; SMN2 (0.55) | TSHRALDH1A1GAASMN1; SMN2AKR1C3 | |
| SCHEMBL14247599 | 0.79 | P2RX7 (0.52) | TRPV1ALDH1A1SMN1; SMN2 | |
| SCHEMBL6603738 | 0.77 | CYP2C9 (0.73) | CYP2C9TSHRCYP3A4TRPV1ALDH1A1 | |
| SCHEMBL7368202 | 0.77 | ITGB3 (0.67) | CYP2C9CYP3A4ALDH1A1SMN1; SMN2ITGB3 | |
| SCHEMBL19265759 | 0.77 | ALDH1A1 (0.58) | ALDH1A1GAASMN1; SMN2 | |
| SCHEMBL13801421 | 0.77 | MAPT (0.58) | SMN1; SMN2ITGB3ITGA2BCHRM1 | |
| SCHEMBL16599286 | 0.77 | AKR1C3 (0.58) | CYP2C9TSHRCYP3A4TRPV1ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090163480-A1 | Modified amino acids, pharmaceuticals containing these compounds and method for their production | DR. KARL THOMAE GMBH (DE) | 2009-06-25 | — | — | US | disclosed |
| US-20090163480-A1 | Modified amino acids, pharmaceuticals containing these compounds and method for their production | DR. KARL THOMAE GMBH (DE) | 2009-06-25 | — | — | US | disclosed |
| US-7498325-B2 | Modified amino acids, pharmaceuticals containing these compounds and method for their production | KARL THOMAS GMBH (DE) | 2009-03-03 | — | — | US | disclosed |
| US-7498325-B2 | Modified amino acids, pharmaceuticals containing these compounds and method for their production | KARL THOMAS GMBH (DE) | 2009-03-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090163480-A1 | Modified amino acids, pharmaceuticals containing these compounds and method for their production | PTMS, CHRM1, SRMS | CYP2C9 1340/4885TSHR 181/4885CYP2D6 1677/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.